Other Corporate Information – Page 7 – Alligator Bioscience

All IR MAR Regulatory Report

2025-05-09

Alligator Bioscience completes Phase 3 GMP manufacturing of mitazalimab, remains on track for trial initiation with partner

Lund, Sweden, 9 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the successful completion of the manufacture ...

2025-05-08

Regulatory

Alligator Bioscience updates dividend policy

Alligator Bioscience AB (publ) today announces an update to its dividend policy following the constitution of Alligator’s new Board of ...

2025-04-282025-04-30

Regulatory

Exercise price determined for the exercise of warrants series TO 12 in Alligator Bioscience AB

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-04-232025-05-28

Alligator Bioscience announces initiation of HLX22 Phase 2 trial in breast cancer by Shanghai Henlius Biotech, Inc.

Lund, Sweden – 23 April 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Shanghai Henlius Biotech, Inc. (“He ...

2025-04-012025-04-16

Regulatory

Alligator Bioscience determines record date for reverse share split of ordinary shares and reminds of the recalculation of warrants

The board of directors of Alligator Bioscience AB (“Alligator Bioscience” or the “Company”) has resolved that the re ...

2025-03-21

Alligator Bioscience announces leadership transition in clinical development

Lund, Sweden – 21 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chi ...

2025-03-202025-05-28

Alligator Bioscience Announces FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer

Lund, Sweden – 20 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FD ...

2025-02-26

Alligator Bioscience Announces Continued Encouraging Overall Survival Benefit for Mitazalimab

Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy alone Topline da ...

2025-02-25

Regulatory

The Board of Directors of Alligator Bioscience propose a reverse share split of ordinary shares

The Board of Directors of Alligator Bioscience AB (“Alligator Bioscience” or the ”Company”) proposes that an Extraor ...